Search clinical trials for: Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation

Total 141 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
Duke University
Centers for Disease Control and Prevention; Children's Hospital Medical Center...

Completed

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (Tdap/IIV)

Pregnancy

United States
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Dermatitis, Atopic

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
Children's Hospital Medical Center, Cincinnati

Completed

Flu Vaccine Study in Neuromuscular Patients 2011

Duchenne Muscular Dystrophy | Spinal Muscular Atrophy | Congenital Muscular Dystrophy
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Influence of Chronic CMV Infection on Influenza Vaccine Responses (SLVP025)

Influenza | Cytomegalovirus Infections

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

Seasonal Influenza

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Influenza Virus Vaccines in Children and Adults

Influenza

United States
PharmaJet, Inc.

Completed

Jet Injection for Influenza (JIFI)

Influenza, Human

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Seqirus

Completed

A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

Influenza

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
University Health Network, Toronto

Completed

High Dose vs. Standard Influenza Vaccine in Adult SOT

Influenza | Immunosuppression

Canada
University of Sao Paulo General Hospital

Completed

Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases

Sjogren's Syndrome | Systemic Lupus

Brazil
Liquidia Technologies, Inc.
Children's Hospital Medical Center, Cincinnati; Accelovance

Completed

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 (LIfT)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Children

Influenza

United States
Sinovac Biotech Co., Ltd

Completed

The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine

Influenza

China
Emory University

Completed

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination (FLU1)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Influenza

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
International Vaccine Institute

Completed

Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route

Healthy

Korea, Republic of
Sanofi

Completed

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Influenza | Myxovirus Infection | Orthomyxoviruses

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Influenza

Australia, Philippines
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

Seasonal Influenza

Italy
PharmaJet, Inc.

Completed

Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe

Influenza Prophylaxis

United States
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza

United Kingdom
Crucell Holland BV

Completed

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers

Influenza

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)

Influenza

France
The University of Hong Kong
Hospital Authority, Hong Kong

Completed

2010/2011 Trivalent Influenza Vaccination

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Influenza

Switzerland
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Influenza

United States
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy and Safety of Influenza Vaccine During Sarcoidosis (SARCOVAC)

Influenza Vaccine | Sarcoidosis

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Trial to Collect Safety Data and Sera for Immunogenicity Testing

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

Influenza

United States

3

Subscribe